C. Kelly

发表

Treating Clostridium difficile infection with fecal microbiota transplantation.

J. Bakken, T. Borody, L. Brandt, 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.

Jilly F. Evans, C. Kelly, S. Kargman, 2003, Cancer research.

Racial Differences in Clostridium difficile Infection Rates Are Attributable to Disparities in Health Care Access

J. Machan, C. Kelly, E. Mao, 2015, Antimicrobial Agents and Chemotherapy.

Fecal Microbiota Transplantation for Relapsing Clostridium difficile Infection in 26 Patients: Methodology and Results

C. Kelly, Niren Jasutkar, Lauren de Leon, 2012, Journal of clinical gastroenterology.

Weight Gain After Fecal Microbiota Transplantation

C. Kelly, Neha Alang, 2015, Open forum infectious diseases.

Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel

H. Tilg, A. Gasbarrini, J. Keller, 2020, The Lancet Gastroenterology & Hepatology.

Risk Factors for Gastrointestinal Symptoms Following Successful Eradication of Clostridium difficile by Fecal Microbiota Transplantation (FMT)

C. Kelly, Z. Kassam, J. Allegretti, 2019, Journal of clinical gastroenterology.

Donor Screening for Fecal Microbiota Transplantation.

M. Osman, C. Kelly, Z. Kassam, 2019, The New England journal of medicine.

Long-Term Outcomes Following Multiply Recurrent Clostridioides Difficile Infection and Fecal Microbiota Transplantation.

Ravy K. Vajravelu, C. Brensinger, L. Laine, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Manipulating the Microbiome With Fecal Transplantation to Treat Ulcerative Colitis.

A. Ananthakrishnan, C. Kelly, 2019, JAMA.

SARS-CoV-2 vaccines and donor recruitment for FMT

H. Tilg, A. Gasbarrini, J. Keller, 2021, The Lancet Gastroenterology & Hepatology.

Hair Growth in Two Alopecia Patients after Fecal Microbiota Transplant

C. Kelly, P. Lio, E. Yen, 2017, ACG case reports journal.

Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection.

C. Kelly, J. Marchesi, B. Mullish, 2020, Inflammatory bowel diseases.

Outcomes of Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Diseases and Recurrent Clostridioides difficile Infection.

C. Kelly, B. Mullish, Z. Kassam, 2020, Gastroenterology.

Stool processing speed and storage duration do not impact the clinical effectiveness of fecal microbiota transplantation

M. Osman, C. Kelly, Z. Kassam, 2020, Gut microbes.

Patients Eligible for Trials of Microbe-based Therapeutics do not Represent the Population With Recurrent Clostridioides difficile Infection.

C. Kelly, J. Allegretti, M. Fischer, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections

C. Kelly, J. Allegretti, N. Stollman, 2021, The American journal of gastroenterology.

Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook.

L. Laine, C. Kelly, T. Moore, 2015, Gastroenterology.

MULTIPLEX PCR BASED URINARY TRACT INFECTION (UTI) ANALYSIS COMPARED TO TRADITIONAL URINE CULTURE IN IDENTIFYING SIGNIFICANT PATHOGENS IN SYMPTOMATIC PATIENTS.

D. E. Smith, H. Korman, C. Kelly, 2019, Urology.

Effectiveness and safety of fecal microbiota transplantation for Clostridioides difficile infection: Results from a 5,344 patient cohort study.

M. Osman, S. Olesen, C. Kelly, 2022, Gastroenterology.

S131 CP101, an Investigational Orally Administered Microbiome Therapeutic, Increases Intestinal Microbiome Diversity and Prevents Recurrent C. difficile Infection: Results From a Randomized, Placebo-Controlled Trial

T. Borody, C. Kelly, D. Pardi, 2021, American Journal of Gastroenterology.

S144 CP101 Engraftment Drives Efficacy: Results From a Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for Prevention of Recurrent C. difficile Infection

T. Borody, C. Kelly, D. Pardi, 2021, American Journal of Gastroenterology.

S145 Week 24 Efficacy and Safety Data from PRISM3: A Randomized, Placebo-Controlled Trial Evaluating CP101, an Investigational Orally Administered Microbiome Therapeutic for the Prevention of Recurrent C. difficile Infection

T. Borody, C. Kelly, D. Pardi, 2021, American Journal of Gastroenterology.

Fecal Microbiota Transplant is Highly Effective in Real-World Practice: Initial Results from the FMT National Registry.

R. Knight, L. Laine, R. Arsenescu, 2020, Gastroenterology.

International consensus conference on stool banking for faecal microbiota transplantation in clinical practice

H. Tilg, A. Gasbarrini, M. Nieuwdorp, 2019, Gut.

A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection.

M. Henn, C. Kelly, M. Vulić, 2016, The Journal of infectious diseases.

Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic

H. Tilg, A. Gasbarrini, J. Keller, 2020, Gut.

The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications

C. Kelly, B. Mullish, J. Allegretti, 2019, The Lancet.

Fecal Microbiota Transplant for Treatment of Clostridium difficile Infection in Immunocompromised Patients

M. Mellow, T. Borody, L. Brandt, 2014, The American Journal of Gastroenterology.

Guidance on preparing an investigational new drug application for fecal microbiota transplantation studies.

C. Kelly, A. Khoruts, S. Kunde, 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Fecal Transplant in Inflammatory Bowel Disease.

C. Kelly, A. Browne, 2017, Gastroenterology clinics of North America.

FMT in Clostridium difficile and Other Potential Uses

C. Kelly, S. Fine, 2017 .

Update on FMT 2015: Indications, Methodologies, Mechanisms and Outlook

L. Laine, C. Kelly, T. Moore, 2015 .

The 5D framework: a clinical primer for fecal microbiota transplantation to treat Clostridium difficile infection.

M. Osman, C. Kelly, Z. Kassam, 2018, Gastrointestinal endoscopy.

Systematic review: the global incidence of faecal microbiota transplantation‐related adverse events from 2000 to 2020

C. Kelly, G. Ianiro, Bota Cui, 2020, Alimentary pharmacology & therapeutics.

Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice

M. Kamm, T. Borody, C. Kelly, 2020, Gut.

Nuts and Bolts of Fecal Microbiota Transplantation

C. Kelly, J. Allegretti, M. Fischer, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

The AGA's Fecal Microbiota Transplantation National Registry: An Important Step Toward Understanding Risks and Benefits of Microbiota Therapeutics.

L. Laine, C. Kelly, Gary D. Wu, 2017, Gastroenterology.

Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection

J. Machan, L. Brandt, C. Kelly, 2016, Annals of Internal Medicine.

An analysis of the supply chain of cacao in Colombia

C. Kelly, M. Lundy, P. Abbott, 2018 .

Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection.

C. Kelly, Lauren de Leon, J. Watson, 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Long-Term Follow-Up of Colonoscopic Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection

Neil Stollman, Tina Park, Colleen Kelly, 2012, The American Journal of Gastroenterology.

Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease

M. Mellow, D. Rex, H. Sokol, 2016, Inflammatory bowel diseases.

FMT: What's Next? A Narrative Review of Fecal Microbiota Transplantation in Clostridioides difficile Infection and Inflammatory Bowel Disease.

C. Kelly, Sohum A. Patwa, Christopher Ward, 2022, Rhode Island medical journal.

Factors Associated with the Use of Fecal Microbiota Transplant in Patients with Recurrent Clostridium difficile Infections

C. Kelly, Seah H. Lim, Sehrish Jamot, 2018, Infection Control & Hospital Epidemiology.

Understanding the Scope of Do-It-Yourself Fecal Microbiota Transplant.

C. Kelly, Anna Wexler, C. Lillis, 2020, The American journal of gastroenterology.

Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection

C. Kelly, E. Hohmann, David A. Lombardi, 2023, JAMA network open.

Long-term Follow-up Study of Fecal Microbiota Transplantation for Severe and/or Complicated Clostridium difficile Infection: A Multicenter Experience

M. Mellow, T. Borody, L. Brandt, 2015, Journal of clinical gastroenterology.

A High Rate of Alternative Diagnoses in Patients Referred for Presumed Clostridium difficile Infection

J. Machan, C. Kelly, Melissa F. Jackson, 2016, Journal of clinical gastroenterology.

Fecal Microbiota Transplantation for Severe or Fulminant Clostridioides difficile Infection: Systematic Review and Meta-analysis

E. McArthur, C. Kelly, G. Ianiro, 2021, Journal of the Canadian Association of Gastroenterology.

Cost‐effectiveness analysis of sequential fecal microbiota transplantation for fulminant Clostridioides difficile infection

C. Kelly, Z. Kassam, J. Allegretti, 2021, Journal of gastroenterology and hepatology.

Risk Factors that Predict the Failure of Multiple Fecal Microbiota Transplantations for Clostridioides difficile Infection

C. Kelly, Huiping Xu, D. Kao, 2020, Digestive Diseases and Sciences.

Long-Term Efficacy and Safety of Fecal Microbiota Transplantation for Treatment of Recurrent Clostridioides difficile Infection

C. Kelly, J. Allegretti, J. Marcus, 2020, Journal of clinical gastroenterology.

FMT in IBD: What Have We Learned?

C. Kelly, J. Allegretti, 2017, Digestive Diseases and Sciences.

Predictors of Early Failure After Fecal Microbiota Transplantation for the Therapy of Clostridium Difficile Infection: A Multicenter Study

C. Kelly, A. Keshteli, Huiping Xu, 2016, The American Journal of Gastroenterology.

The Long-term Efficacy and Safety of Fecal Microbiota Transplant for Recurrent, Severe, and Complicated Clostridium difficile Infection in 146 Elderly Individuals

T. Borody, L. Brandt, C. Kelly, 2015, Journal of clinical gastroenterology.

Fecal Microbiota Transplantation

C. Kelly, 2014 .

Analysis of gut microbiota – An ever changing landscape

C. Heiner, L. Brandt, C. Kelly, 2017, Gut microbes.

The regulation of fecal microbiota for transplantation: An international perspective for policy and public health

C. Kelly, J. Daw, Mark B. Smith, 2015 .

Donor screening for fecal microbiota transplantation in China: Evaluation of 8,483 candidates.

C. Kelly, Z. Kassam, Qiyi Chen, 2021, Gastroenterology.

Fecal Microbiota Transplantation for Ulcerative Colitis: Not Just Yet.

C. Kelly, A. Grinspan, 2015, Gastroenterology.

Complete Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium difficile Infection following Fecal Microbiota Transplantation

L. Brandt, C. Kelly, A. Khoruts, 2016, mBio.

Effectiveness and safety of colonic and capsule fecal microbiota transplantation for recurrent Clostridioides difficile infection.

C. Kelly, A. Khoruts, J. Allegretti, 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Management of Severe and Severe/Complicated Clostridoides difficile Infection using Sequential Fecal Microbiota Transplant by Retention Enema.

Lanre Jimoh, C. Kelly, A. Rupawala, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Current Landscape and Lessons from Fecal Microbiota Transplantation for Inflammatory Bowel Disease: Past, Present, and Future

C. Kelly, Z. Kassam, J. Allegretti, 2017, Inflammatory bowel diseases.

Donor Stool Processing Time: The Effect on the Intestinal Microbiome and Clinical Outcomes of Fecal Microbiota Transplantation in Clostridium Difficile Infection

M. Osman, C. Kelly, Z. Kassam, 2017 .

The Association of Stool Donor Diet on Microbial Profile and Clinical Outcomes of Fecal Microbiota Transplantation in Clostridium Difficile Infection

M. Osman, C. Kelly, Z. Kassam, 2017 .

Predictors of Failure After Fecal Microbiota Transplantation (FMT) for the Therapy of Clostridium difficile Infection (CDI): 1335

C. Kelly, Huiping Xu, B. Sipe, 2015 .

A Challenging Case of Diarrhea After Fecal Microbiota Transplant: 360

C. Kelly, Melissa F. Jackson, Sidney Olefson, 2015 .

Editorial: a simple faecal preparation protocol for faecal microbiota transplantation

C. Kelly, 2015, Alimentary pharmacology & therapeutics.

Safety Outcomes After Fecal Microbiota Transplantation (FMT) For C. difficile Infection (CDI): 714

C. Kelly, D. Rahni, De Wilson, 2014 .

Barriers to Greater Utilization of Fecal Bacteriotherapy for Chronic Clostridium difficile Infection: 368

D. Kerstetter, C. Kelly, L. D. Leon, 2010 .

Redefining Clostridioides difficile infection antibiotic response and clinical outcomes.

K. Garey, E. Kuijper, C. Kelly, 2023, The Lancet. Infectious diseases.

7 – The Icon Study: Inflammatory Bowel Disease and Recurrent Clostridium Difficile Infection: Outcomes After Fecal Microbiota Transplantation

C. Kelly, J. Marchesi, B. Mullish, 2019, Gastroenterology.

Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer

C. Kelly, M. Wolfe, M. Yao, 2004, British Journal of Cancer.

C. Kelly, L. Laine, Gary D. Wu, 2020, Journal of hypertension.

Is it unethical to conduct placebo-controlled trials of faecal microbiota transplantation for recurrent Clostridioides difficile infection?

C. Kelly, S. Kahn, 2020, The lancet. Gastroenterology & hepatology.

Tu1519: CP101, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC FOR THE PREVENTION OF RECURRENT C. DIFFICILE INFECTION: A COMBINED ANALYSIS OF THE PRISM3 (RANDOMIZED PLACEBO-CONTROLLED) AND PRISM-EXT (OPEN-LABEL) TRIALS

C. Kelly, J. Allegretti, S. Khanna, 2022, Gastroenterology.

Enterotoxigenic Clostridium perfringens Infection as an Adverse Event After Faecal Microbiota Transplantation in Two Patients With Ulcerative Colitis and Recurrent Clostridium difficile Infection: A Neglected Agent in Donor Screening.

C. Kelly, M. Azimirad, H. Asadzadeh Aghdaei, 2019, Journal of Crohn's & colitis.

Efficacy, Safety, and Cost-effectiveness of Bezlotoxumab in Preventing Recurrent Clostridioides difficile Infection: Systematic Review and Meta-analysis.

C. Kelly, J. Asemota, Azizullah Beran, 2023, Journal of clinical gastroenterology.

Annals for Hospitalists Inpatient Notes - Clinical Pearls-Updates on Clostridioides difficile Infection for Hospitalists.

C. Kelly, D. Marino, 2022, Annals of internal medicine.

Monitoring Fecal Microbiota Transplantation Practice in a Rapidly Evolving Health and Regulatory Environment

L. Laine, C. Kelly, Gary D. Wu, 2020, Gastroenterology.

The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications

C. Kelly, B. Mullish, J. Allegretti, 2019, The Lancet.

Fecal Microbiota Transplantation for Relapsing Clostridium difficile Infection in 26 Patients: Methodology and Results

C. Kelly, Niren Jasutkar, Lauren de Leon, 2012, Journal of clinical gastroenterology.

Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection.

C. Kelly, Lauren de Leon, J. Watson, 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.